A single needle stick may soon do what daily pills have done for decades: crush cholesterol at its genetic source, permanently.
Quick Take
- A phase 1 human trial of VERVE-102, a gene-editing drug, cut PCSK9 protein by up to 88% and LDL cholesterol by up to 62% after just one dose.
- The therapy edits the PCSK9 gene inside liver cells, aiming to lower cholesterol for life instead of requiring daily pills or repeat shots.
- Eli Lilly and Verve Therapeutics reported the results at the European Atherosclerosis Society Congress and in the New England Journal of Medicine on May 25, 2026.
- Only 35 patients have been treated so far, and no study has yet proven the edit prevents heart attacks or strokes.
One Infusion, One Permanent Genetic Edit
Doctors have fought high cholesterol for 40 years with pills, injections, and diet advice. VERVE-102 takes a different approach entirely. It uses base editing, a precision tool that rewrites a single letter of DNA inside liver cells, permanently switching off the PCSK9 gene. That gene normally limits how well the liver clears LDL cholesterol from the blood. Turn it off, and the liver keeps pulling cholesterol out of circulation on its own, indefinitely.
The trial enrolled 35 adults with heterozygous familial hypercholesterolemia or premature coronary artery disease, two groups long stuck with dangerously high LDL despite standard treatment. Researchers gave each patient one intravenous infusion, then tracked their blood work. At the highest dose, PCSK9 protein dropped by 88% and LDL cholesterol fell 62%, according to the peer-reviewed results published in the New England Journal of Medicine.
Eli Lilly, which owns Verve Therapeutics, announced the findings the same day the study posted, calling it evidence the treatment could work as a one-time therapy for high cholesterol. That framing matters because every current cholesterol drug, statins, ezetimibe, PCSK9 antibodies, requires ongoing use. Skip a dose and the numbers creep back up. A one-time edit removes that burden entirely, assuming the effect holds.
Early Signs Point To Lasting Effect, Not Just A Quick Dip
Early results suggest the drop is not temporary. Researchers followed 15 participants for at least a year and found the cholesterol reduction held steady the whole time, according to the published abstract. That distinguishes this data from a short-term biomarker blip. Sustained suppression over 12 months is the kind of signal doctors look for before believing an edit truly stuck rather than fading as cells turn over.
Safety data so far also looks clean. Researchers reported no dose-limiting toxic effects among treated patients. No serious liver damage, no dangerous immune reactions, nothing that forced doctors to stop escalating the dose. For a treatment that rewrites DNA permanently, that clean safety record at every dose tested is the detail cardiologists will watch closest as the trial expands.
Why Doctors Still Call This Early, Not Proven
The trial had no placebo group and no blinding, standard limits for a first-in-human study focused on safety and dosing rather than proof of benefit. Thirty-five patients is also a small group. Rare side effects, or differences across age, sex, or ethnic background, may not show up until far more people are treated. None of that undercuts the results reported. It simply means the next phase of testing needs to be bigger and longer before doctors call this a cure.
That caution fits a pattern seen across gene-editing research this year. A separate CRISPR therapy targeting a different cholesterol gene, ANGPTL3, showed similar one-year durability in another trial, reinforcing that editing DNA to permanently silence a single gene is becoming a real strategy in heart medicine, not just a lab curiosity. The American College of Cardiology has already issued a formal statement tracking the field’s rapid movement toward patient use.
What Happens Before This Reaches Your Doctor’s Office
Verve and Lilly still need larger trials that measure something statins already prove: fewer heart attacks, strokes, and deaths over years, not just better lab numbers after 12 months. Regulators will almost certainly demand that evidence before approving a permanent genetic edit for widespread use, since a bad batch of side effects cannot be undone the way a discontinued pill can. That higher bar is reasonable given the stakes involved.
Gene hacking isn’t science fiction anymore.
Researchers are already editing genes like PCSK9 and ANGPTL3 in humans—and in early trials, a single infusion dropped LDL cholesterol by as much as 62%, with effects still showing up more than a year later.
These are still tiny Phase… pic.twitter.com/wIKBiZLOyU
— Dr. Alex Tatem (@DrAlexTatem) September 11, 2026
Statins, ezetimibe, and injectable PCSK9 blockers already work and already have decades of safety data behind them. Any gene-editing therapy has to prove it beats that track record, not just match it, before families should trade a daily pill for a permanent DNA change. The early numbers here are genuinely striking. Whether they translate into fewer heart attacks is the question the next several years of testing will have to answer.
Sources:
mindbodygreen.com, pubmed.ncbi.nlm.nih.gov, nejm.org, phys.org
